Text this: Response to "Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab vs. Dupilumab in Moderate to Severe Atopic Dermatitis'"